Mechanism of action of (E,E)-bisantrene

Magipics has created an animation for Racura Oncology, a clinical biopharmaceutical company with a mission to silence cancer.

The animation describes a novel therapeutic approach to target MYC-driven cancers using Racura Oncology’s (E,E)-bisantrene drug. The drug has been shown in preclinical studies to bind and stabilise a normally unstable G-quadruplex. By locking this structure in place, (E,E)-bisantrene is believed to silence MYC transcription, evidenced through suppressed MYC mRNA levels in preclinical studies.

This mechanism represents a novel therapeutic approach being investigated by Racura Oncology to target MYC-driven cancers, with the potential to improve patient outcomes.

Click on the image below to view the animation.